Physician profile
Paul E Roa
NPI 1861717092
$12,267.27
in general payments reported to CMS, 2019-2025
27 companies · $1,961 in 2025
The $1,961 reported for 2025 was more than what 82% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,553 · 2020: $1,448 · 2021: $1,766 · 2022: $2,107 · 2023: $1,903 · 2024: $1,530 · 2025: $1,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,393.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,974.74 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Nevro Corp. | $1,810.67 | 2019-2024 | Senza |
| Vertos Medical, INC. | $1,665.73 | 2019-2022 | |
| Globus Medical, INC. | $1,262.94 | 2025 | Senza, Vyrsa V1 |
| Forte Bio-Pharma LLC | $1,238.28 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Abbott Laboratories | $935.37 | 2019-2025 | Proclaim, Eterna |
| Nalu Medical, INC. | $863.90 | 2021-2024 | Nalu Neurostimulation System |
| Scilex Pharmaceuticals INC. | $585.77 | 2019-2023 | Ztlido |
| Stryker Corporation | $520.38 | 2019-2024 | Mild Device Kit |
| Collegium Pharmaceutical, INC. | $333.90 | 2019-2025 | Xtampza |
| Spinal Simplicity, LLC | $248.83 | 2023-2025 | Ha Minuteman G3-R |
| Medtronic USA, INC. | $174.18 | 2019-2020 | |
| Pacira Therapeutics, INC. | $128.06 | 2020-2021 | |
| Depuy Synthes Sales INC. | $122.15 | 2019-2023 | Orthovisc, Monovisc |
| Medtronic, INC. | $79.21 | 2021-2023 | Intellis Adaptivestim |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $53.45 | 2020 | |
| Electronic Waveform Lab, INC. | $52.53 | 2019-2025 | |
| Ibsa Pharma INC. | $35.02 | 2023 | Tirosint, Licart |
| Pfizer INC. | $31.85 | 2019 | |
| Biotissue Holdings INC. | $31.50 | 2023 | |
| Biodelivery Sciences International, INC. | $30.08 | 2019 | |
| Zyla Life Sciences, INC. | $21.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.61 | 2024 | Austedo Xr |
| Si-Bone, INC. | $15.44 | 2022 | |
| Redhill Biopharma INC. | $14.98 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.89 | 2022 | |
| Saluda Medical Americas, INC. | $3.27 | 2024 | Evoke |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Roa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.